LobbyingAquestive Therapeutics lobbying by quarter
Aquestive Therapeutics AQST's latest lobbying report covers Q2 2026, at $60K. The four quarters Q3 2025–Q2 2026 total $230K. Its first report covers Q4 2022; the issues it reports most are Pharmacy and Health Issues.
Aquestive TherapeuticsAQST
- Latest quarter
- $60K
- Q2 2026 · 1 reports
- Last 12 months
- $230K
- Last 4 quarters
- vs last quarter
- 0.0%
- Q2 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $45K | 2 |
| Q1 2023 | $0 | 2 |
| Q2 2023 | $45K | 2 |
| Q3 2023 | $45K | 1 |
| Q4 2023 | $45K | 1 |
| Q1 2024 | $45K | 1 |
| Q2 2024 | $0 | 0 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $20K | 1 |
| Q2 2025 | $30K | 1 |
| Q3 2025 | $50K | 1 |
| Q4 2025 | $60K | 1 |
| Q1 2026 | $60K | 1 |
| Q2 2026 | $60K | 1 |
Policy issues the reports name
- Pharmacy8 reports
- Health issues5 reports
- Consumer protection and safety4 reports
A report that names several issues counts once for each.
Who was lobbied
- Food & Drug Administration (FDA)9 reports
- Consumer Product Safety Commission (CPSC)4 reports
- HOUSE OF REPRESENTATIVES4 reports
- SENATE4 reports
- Health & Human Services, Dept of (HHS)3 reports
- Office of Management & Budget (OMB)1 reports
- White House Office1 reports
Firms it paid
| Firm | ||
|---|---|---|
| Bracewell | $230K | 4 quarters |
| Rubicon Advisors | $225K | 6 quarters |
| Steptoe | $50K | 5 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| EDWARD KRENIK | Assoc. Admin. Cong. Affairs, EPA (2001-03); Leg.Director,Rep. Frelinghuysen (1994-01); Leg. Asst/Assoc.Staff, Rep.Dean Gallo (1989-94); Leg. Asst. Sen. Durenberger(1987-89) | Q4 2025 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/16for Q2 | Bracewell | $60K |
| 04/17for Q1 | Bracewell | $60K |
| 01/20for Q4 2025 | Bracewell | $60K |
| 25/10/20for Q3 2025 | Bracewell | $50K |
| 25/07/22for Q3 2025 | Bracewell | Under $5,000 |
| 25/07/21for Q2 2025 | Steptoe | $30K |
| 25/04/21for Q1 2025 | Steptoe | $20K |
| 25/04/17for Q1 2025 | Steptoe | Under $5,000 |
| 24/07/21for Q1 2023 | Rubicon Advisors | Under $5,000 |
| 24/05/08for Q1 2024 | Rubicon Advisors | $45K |
| 24/01/25for Q4 2023 | Rubicon Advisors | $45K |
| 23/10/22for Q3 2023 | Rubicon Advisors | $45K |
| 23/07/23for Q2 2023 | Rubicon Advisors | $45K |
| 23/07/18for Q2 2023 | Steptoe | Under $5,000 |
| 23/04/20for Q1 2023 | Rubicon Advisors | $45K |
| 23/04/20for Q1 2023 | Steptoe | Under $5,000 |
| 23/01/20for Q4 2022 | Steptoe | Under $5,000 |
| 23/01/16for Q4 2022 | Rubicon Advisors | $45K |